| Biomarker ID | 1537 |
| PMID | 25227682 |
| Year | 2014 |
| Biomarker | Ki-67 |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in patients with early relapse |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathway include: DNA Damage; Neuroscience; Primary Focal Segmental Glomerulosclerosis FSGS |
| Experiment | Early Relapse Vs No Relapse |
| Type of Biomarker | Prognostic |
| Cohort | 60 cases of prostate cancer were included for the analysis, Straified by patients with EBRT - external beam radiotherapy (n=15 Relapse, n=15 no relapse); and PADT - primary androgen deprivation therapy (n=15 relapse; n=15 no relapse) |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | EBRT cohort: p=0.0006; PADT Cohort: p=0.0004 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | NA |